The sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market size has grown rapidly in recent years. It will grow from $0.68 billion in 2025 to $0.75 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to increasing prevalence of sexually transmitted infections, limitations of traditional diagnostic methods, growing awareness of women’s reproductive health, expansion of clinical diagnostic laboratories, adoption of standard pcr testing protocols.
The sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market size is expected to see strong growth in the next few years. It will grow to $1.08 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to rising demand for point-of-care molecular diagnostics, technological advancements in multiplex and real-time pcr, increasing adoption of home-based testing solutions, growing investments in molecular diagnostic infrastructure, expanding screening programs for sti and vaginitis. Major trends in the forecast period include rising adoption of multiplex pcr panels for sti and vaginitis detection, increasing preference for rapid and high-sensitivity molecular diagnostics, growing demand for at-home and self-collected pcr testing kits, expansion of pcr testing in routine women’s health screening, enhanced focus on early and accurate pathogen identification.
The rising frequency of sexual health screenings is expected to drive growth in the sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market. Sexual health screenings are medical evaluations performed to detect STIs and related conditions, enabling early diagnosis, timely treatment, and prevention of disease transmission. The increase in screenings is largely due to the global rise in STIs, which underscores the need for prompt and accurate detection to minimize complications and curb further spread. PCR testing plays a vital role in this context by allowing precise identification of pathogens, often even in asymptomatic individuals, facilitating early intervention. For instance, in June 2025, according to GOV.UK, new STI diagnoses in the UK declined by 8.8%, from 399,947 cases in 2023 to 364,750 cases in 2024, reflecting the impact of enhanced screening efforts. Therefore, the growth in sexual health screenings is propelling the expansion of the STI and vaginitis PCR testing market.
Major players in the sexually transmitted infection (STI) and vaginitis PCR testing market are developing technologies like multiplex real-time PCR assays to meet the increasing demand for fast, precise, and comprehensive pathogen detection. Multiplex PCR allows for the simultaneous amplification and identification of DNA or RNA from multiple pathogens within a single test, lowering both turnaround time and costs compared to traditional single-pathogen assays. This method also enhances sensitivity and specificity, enabling the detection of low levels of pathogen genetic material - even in co-infections - that conventional culture or microscopy techniques might overlook or detect less accurately. For instance, in February 2023, Thermo Fisher Scientific, a US-based biotechnology company, introduced the Applied Biosystems TrueMark STI Select Panel, a multiplex real-time PCR assay designed to concurrently detect four prevalent STIs: Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium. Intended for research purposes, this test improves clinical outcomes by offering faster, highly sensitive diagnostics while optimizing laboratory workflows, marking a notable advancement in molecular STI diagnostics.
In December 2024, OraSure Technologies, a US-based medical device and diagnostics company, acquired Sherlock Biosciences for an undisclosed sum. Through this acquisition, OraSure seeks to broaden its molecular diagnostics offerings in sexual health by incorporating Sherlock’s rapid, self-collected STI testing solutions and advancing its entry into the over-the-counter diagnostics market. Sherlock Biosciences, also based in the US, specializes in PCR-based testing for sexually transmitted infections (STIs) and vaginitis.
Major companies operating in the sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Hologic Inc., QIAGEN N.V., ARUP Laboratories Inc., Seegene Inc., LetsGetChecked Ltd., Sansure Biotech Inc., Visby Medical Inc., R-Biopharm AG, Savyon Diagnostics Ltd., altona Diagnostics GmbH, SpeeDx Pty Ltd., CERTEST BIOTEC S.L., ALPCO Diagnostics, Atila Biosystems Inc., Ridacom Diagnostics Ltd., Sinochips Diagnostics Co Ltd., Vitassay S.L., Bioperfectus Technologies Co. Ltd.
North America was the largest region in the sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market in 2025. The regions covered in the sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the sti and vaginitis pcr testing market by increasing the cost of imported reagents, pcr instruments, and molecular consumables, thereby raising overall testing expenses. Diagnostic laboratories and homecare testing segments are particularly affected, with asia-pacific and emerging markets facing higher import duties on molecular diagnostics. These cost pressures have led to pricing adjustments and slower adoption in cost-sensitive regions. However, tariffs have also encouraged local manufacturing of pcr kits and reagents, fostering regional self-reliance and strengthening domestic diagnostic capabilities.
The sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market research report is one of a series of new reports that provides sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market statistics, including sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing industry global market size, regional shares, competitors with a sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market share, detailed sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market segments, market trends and opportunities, and any further data you may need to thrive in the sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing industry. This sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing is a highly accurate molecular diagnostic technique that amplifies and detects the genetic material of pathogens responsible for sexually transmitted and vaginal infections. This method allows for rapid identification of bacteria, viruses, and other microorganisms, enabling healthcare providers to diagnose infections effectively and customize treatments.
The primary test types for STI and vaginitis PCR testing include STI PCR panels and vaginitis PCR panels. STIs are infections caused by bacteria, viruses, fungi, or parasites, primarily transmitted through sexual contact, including vaginal, anal, and oral sex. These tests cover a broad spectrum of sexually transmitted and vaginal infections and are used by various end users such as hospitals and clinics, diagnostic laboratories, and homecare or at-home testing services.
The sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market consists of revenues earned by entities by providing services such as clinical consultations, comprehensive screening tests, multiplex testing, treatment monitoring, and sample collection guidance. The market value includes the value of related goods sold by the service provider or included within the service offering. The sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market also includes sales of nucleic acid extraction kits, positive and negative control materials, automated PCR analyzers, and single-pathogen PCR test kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market size is expected to see strong growth in the next few years. It will grow to $1.08 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to rising demand for point-of-care molecular diagnostics, technological advancements in multiplex and real-time pcr, increasing adoption of home-based testing solutions, growing investments in molecular diagnostic infrastructure, expanding screening programs for sti and vaginitis. Major trends in the forecast period include rising adoption of multiplex pcr panels for sti and vaginitis detection, increasing preference for rapid and high-sensitivity molecular diagnostics, growing demand for at-home and self-collected pcr testing kits, expansion of pcr testing in routine women’s health screening, enhanced focus on early and accurate pathogen identification.
The rising frequency of sexual health screenings is expected to drive growth in the sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market. Sexual health screenings are medical evaluations performed to detect STIs and related conditions, enabling early diagnosis, timely treatment, and prevention of disease transmission. The increase in screenings is largely due to the global rise in STIs, which underscores the need for prompt and accurate detection to minimize complications and curb further spread. PCR testing plays a vital role in this context by allowing precise identification of pathogens, often even in asymptomatic individuals, facilitating early intervention. For instance, in June 2025, according to GOV.UK, new STI diagnoses in the UK declined by 8.8%, from 399,947 cases in 2023 to 364,750 cases in 2024, reflecting the impact of enhanced screening efforts. Therefore, the growth in sexual health screenings is propelling the expansion of the STI and vaginitis PCR testing market.
Major players in the sexually transmitted infection (STI) and vaginitis PCR testing market are developing technologies like multiplex real-time PCR assays to meet the increasing demand for fast, precise, and comprehensive pathogen detection. Multiplex PCR allows for the simultaneous amplification and identification of DNA or RNA from multiple pathogens within a single test, lowering both turnaround time and costs compared to traditional single-pathogen assays. This method also enhances sensitivity and specificity, enabling the detection of low levels of pathogen genetic material - even in co-infections - that conventional culture or microscopy techniques might overlook or detect less accurately. For instance, in February 2023, Thermo Fisher Scientific, a US-based biotechnology company, introduced the Applied Biosystems TrueMark STI Select Panel, a multiplex real-time PCR assay designed to concurrently detect four prevalent STIs: Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium. Intended for research purposes, this test improves clinical outcomes by offering faster, highly sensitive diagnostics while optimizing laboratory workflows, marking a notable advancement in molecular STI diagnostics.
In December 2024, OraSure Technologies, a US-based medical device and diagnostics company, acquired Sherlock Biosciences for an undisclosed sum. Through this acquisition, OraSure seeks to broaden its molecular diagnostics offerings in sexual health by incorporating Sherlock’s rapid, self-collected STI testing solutions and advancing its entry into the over-the-counter diagnostics market. Sherlock Biosciences, also based in the US, specializes in PCR-based testing for sexually transmitted infections (STIs) and vaginitis.
Major companies operating in the sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Hologic Inc., QIAGEN N.V., ARUP Laboratories Inc., Seegene Inc., LetsGetChecked Ltd., Sansure Biotech Inc., Visby Medical Inc., R-Biopharm AG, Savyon Diagnostics Ltd., altona Diagnostics GmbH, SpeeDx Pty Ltd., CERTEST BIOTEC S.L., ALPCO Diagnostics, Atila Biosystems Inc., Ridacom Diagnostics Ltd., Sinochips Diagnostics Co Ltd., Vitassay S.L., Bioperfectus Technologies Co. Ltd.
North America was the largest region in the sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market in 2025. The regions covered in the sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the sti and vaginitis pcr testing market by increasing the cost of imported reagents, pcr instruments, and molecular consumables, thereby raising overall testing expenses. Diagnostic laboratories and homecare testing segments are particularly affected, with asia-pacific and emerging markets facing higher import duties on molecular diagnostics. These cost pressures have led to pricing adjustments and slower adoption in cost-sensitive regions. However, tariffs have also encouraged local manufacturing of pcr kits and reagents, fostering regional self-reliance and strengthening domestic diagnostic capabilities.
The sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market research report is one of a series of new reports that provides sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market statistics, including sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing industry global market size, regional shares, competitors with a sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market share, detailed sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market segments, market trends and opportunities, and any further data you may need to thrive in the sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing industry. This sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing is a highly accurate molecular diagnostic technique that amplifies and detects the genetic material of pathogens responsible for sexually transmitted and vaginal infections. This method allows for rapid identification of bacteria, viruses, and other microorganisms, enabling healthcare providers to diagnose infections effectively and customize treatments.
The primary test types for STI and vaginitis PCR testing include STI PCR panels and vaginitis PCR panels. STIs are infections caused by bacteria, viruses, fungi, or parasites, primarily transmitted through sexual contact, including vaginal, anal, and oral sex. These tests cover a broad spectrum of sexually transmitted and vaginal infections and are used by various end users such as hospitals and clinics, diagnostic laboratories, and homecare or at-home testing services.
The sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market consists of revenues earned by entities by providing services such as clinical consultations, comprehensive screening tests, multiplex testing, treatment monitoring, and sample collection guidance. The market value includes the value of related goods sold by the service provider or included within the service offering. The sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market also includes sales of nucleic acid extraction kits, positive and negative control materials, automated PCR analyzers, and single-pathogen PCR test kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market Characteristics
3. Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market Supply Chain Analysis
4. Global Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market Trends and Strategies
5. Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market Analysis of End Use Industries
7. Global Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Total Addressable Market (TAM) Analysis for the Market
9. Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market Segmentation
10. Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market Regional and Country Analysis
11. Asia-Pacific Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
12. China Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
13. India Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
14. Japan Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
15. Australia Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
16. Indonesia Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
17. South Korea Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
18. Taiwan Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
19. South East Asia Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
20. Western Europe Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
21. UK Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
22. Germany Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
23. France Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
24. Italy Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
25. Spain Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
26. Eastern Europe Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
27. Russia Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
28. North America Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
29. USA Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
30. Canada Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
31. South America Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
32. Brazil Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
33. Middle East Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
34. Africa Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market
36. Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market Competitive Landscape and Company Profiles
37. Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market Other Major and Innovative Companies
40. Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Sexually Transmitted Infection (STI) And Vaginitis Polymerase Chain Reaction (PCR) Testing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Test Type: Sexually Transmitted Infection (STR) Polymerase Chain Reaction (PCR) Panels; Vaginitis Polymerase Chain Reaction (PCR) Panels2) By Condition: Sexually Transmitted Infections; Vaginal Infections
3) By End User: Hospitals And Clinics; Diagnostic Laboratories; Homecare Or At-Home Testing; Other End Users
Subsegments:
1) By Sexually Transmitted Infection (STR) Polymerase Chain Reaction (PCR) Panels: Chlamydia Trachomatis Polymerase Chain Reaction; Neisseria Gonorrhoeae Polymerase Chain Reaction; Trichomonas Vaginalis Polymerase Chain Reaction; Herpes Simplex Virus Polymerase Chain Reaction; Human Papillomavirus Polymerase Chain Reaction; Mycoplasma Genitalium Polymerase Chain Reaction; Syphilis Polymerase Chain Reaction; Multiplex Sexually Transmitted Infection Polymerase Chain Reaction Panels2) By Vaginitis Polymerase Chain Reaction (PCR) Panels: Bacterial Vaginosis Polymerase Chain Reaction; Candida Species Polymerase Chain Reaction; Trichomoniasis Polymerase Chain Reaction; Mixed Vaginitis Polymerase Chain Reaction Panels; Aerobic Vaginitis Polymerase Chain Reaction; Atrophic Vaginitis Polymerase Chain Reaction
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Danaher Corporation; Becton Dickinson and Company; Hologic Inc.; QIAGEN N.V.; ARUP Laboratories Inc.; Seegene Inc.; LetsGetChecked Ltd.; Sansure Biotech Inc.; Visby Medical Inc.; R-Biopharm AG; Savyon Diagnostics Ltd.; altona Diagnostics GmbH; SpeeDx Pty Ltd.; CERTEST BIOTEC S.L.; ALPCO Diagnostics; Atila Biosystems Inc.; Ridacom Diagnostics Ltd.; Sinochips Diagnostics Co Ltd.; Vitassay S.L.; Bioperfectus Technologies Co. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing market report include:- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Danaher Corporation
- Becton Dickinson and Company
- Hologic Inc.
- QIAGEN N.V.
- ARUP Laboratories Inc.
- Seegene Inc.
- LetsGetChecked Ltd.
- Sansure Biotech Inc.
- Visby Medical Inc.
- R-Biopharm AG
- Savyon Diagnostics Ltd.
- altona Diagnostics GmbH
- SpeeDx Pty Ltd.
- CERTEST BIOTEC S.L.
- ALPCO Diagnostics
- Atila Biosystems Inc.
- Ridacom Diagnostics Ltd.
- Sinochips Diagnostics Co Ltd.
- Vitassay S.L.
- Bioperfectus Technologies Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 0.75 Billion |
| Forecasted Market Value ( USD | $ 1.08 Billion |
| Compound Annual Growth Rate | 9.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
